Imsidolimab

Modify Date: 2024-04-06 10:53:16

Imsidolimab structure	Common Name	Imsidolimab
	CAS Number	2102543-86-0	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Imsidolimab

Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases[1][2].

Name	Imsidolimab

Description	Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-36R[1]
References	[1]. Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87(3): AB70. [2]. Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22(9):4344.

No Any Chemical & Physical Properties

Imsidolimab

Use of Imsidolimab

Names

Imsidolimab Biological Activity

Chemical & Physical Properties